Immunization aganist hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 mcg)
Keywords:
DNA recombinant vaccine, Immune response-children, hepatitis B recombinant vaccine, Anti-HBsAbstract
A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9% of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose , to evaluate the antibody response. Our results showed that two and five months after the second dose, 79% and 88% of children seroconverted respectively, reaching 97% after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas.Downloads
Download data is not yet available.
Downloads
Published
1993-02-01
Issue
Section
Serology
How to Cite
Ferreira, C., Yoshida, C., Mercadante, L., Gomes, D., Oliveira, J., França, M., Sidoni, M., Ennes, I., Baptista, M., Schatzmayr, H., & Gaspar, A. (1993). Immunization aganist hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 mcg) . Revista Do Instituto De Medicina Tropical De São Paulo, 35(1), 89-92. https://www.revistas.usp.br/rimtsp/article/view/29002